Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALBTNASDAQ:CURNASDAQ:EVAXNASDAQ:FRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALBTAvalon GloboCare$3.15+4.3%$3.64$2.11▼$12.60$5.97M0.03477,480 shs12,900 shsCURNeuralstem$0.64-7.2%$1.06$1.10▼$13.78$1.34M1.81236,278 shs307,969 shsEVAXEvaxion Biotech A/S$2.77-6.7%$1.86$1.20▼$17.75$3.89M0.1616,767 shs77,307 shsFRTXFresh Tracks Therapeutics$0.94-0.5%$0.94$0.03▼$1.03$5.59M0.542,709 shs2,402 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALBTAvalon GloboCare0.00%-8.70%-13.22%-35.58%-57.20%CURNeuralstem-7.23%-8.12%-8.36%-35.99%-85.74%EVAXEvaxion Biotech A/S0.00%-11.50%+66.87%+55.62%-83.71%FRTXFresh Tracks Therapeutics0.00%0.00%0.00%0.00%-2.71%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALBTAvalon GloboCare2.2225 of 5 stars0.05.00.04.33.01.70.0CURNeuralstemN/AN/AN/AN/AN/AN/AN/AN/AEVAXEvaxion Biotech A/S1.978 of 5 stars3.52.00.00.02.51.70.0FRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALBTAvalon GloboCare 0.00N/AN/AN/ACURNeuralstem 0.00N/AN/AN/AEVAXEvaxion Biotech A/S 3.00Buy$10.00261.01% UpsideFRTXFresh Tracks Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CUR, ALBT, FRTX, and EVAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/2/2025EVAXEvaxion Biotech A/SHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALBTAvalon GloboCare$1.37M4.36N/AN/A($17.22) per share-0.18CURNeuralstem$260K5.17N/AN/A$6.64 per share0.10EVAXEvaxion Biotech A/S$3.29M1.18N/AN/A($5.83) per share-0.48FRTXFresh Tracks Therapeutics$10.06M0.56N/AN/A$1.66 per share0.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALBTAvalon GloboCare-$16.71M-$19.96N/A∞N/A-1,125.59%N/A-73.69%8/18/2025 (Estimated)CURNeuralstem-$4.93MN/A0.00∞N/A-39,417.64%-170.51%-110.16%N/AEVAXEvaxion Biotech A/S-$22.12M-$1.16N/AN/AN/A-347.83%N/A-79.40%8/12/2025 (Estimated)FRTXFresh Tracks Therapeutics-$5.69M-$1.41N/A∞N/AN/AN/AN/AN/ALatest CUR, ALBT, FRTX, and EVAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/27/2025Q1 2025EVAXEvaxion Biotech A/S-$0.65-$0.29+$0.36-$0.29$0.06 millionN/A5/13/2025Q1 2025ALBTAvalon GloboCareN/A-$1.43N/A-$1.43N/AN/A4/1/2025Q4 2024EVAXEvaxion Biotech A/S-$0.26-$0.07+$0.19-$0.07$1.66 million$0.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALBTAvalon GloboCareN/AN/AN/AN/AN/ACURNeuralstemN/AN/AN/AN/AN/AEVAXEvaxion Biotech A/SN/AN/AN/AN/AN/AFRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALBTAvalon GloboCareN/A0.110.11CURNeuralstemN/A2.532.53EVAXEvaxion Biotech A/S7.991.002.80FRTXFresh Tracks TherapeuticsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALBTAvalon GloboCare1.42%CURNeuralstem38.30%EVAXEvaxion Biotech A/S11.04%FRTXFresh Tracks Therapeutics25.04%Insider OwnershipCompanyInsider OwnershipALBTAvalon GloboCare37.30%CURNeuralstem5.38%EVAXEvaxion Biotech A/S41.64%FRTXFresh Tracks Therapeutics0.23%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALBTAvalon GloboCare51.89 million686,000Not OptionableCURNeuralstem62.10 millionN/ANot OptionableEVAXEvaxion Biotech A/S601.40 million685,000No DataFRTXFresh Tracks Therapeutics205.97 million5.96 millionNot OptionableCUR, ALBT, FRTX, and EVAX HeadlinesRecent News About These CompaniesFresh Tracks Therapeutics Announces Dissolution, Initial Cash Distribution and Termination of Trading on the OTC Pink MarketFebruary 26, 2025 | finance.yahoo.comFresh Tracks to cease stock trading as drug company dissolvesFebruary 26, 2025 | bizwest.comFresh Tracks Therapeutics Announces Dissolution, Initial Cash Distribution and Termination of Trading on the OTC Pink MarketFebruary 25, 2025 | prnewswire.comFresh Tracks Therapeutics Announces Appointment of Custodian and Planned DistributionJanuary 27, 2025 | finance.yahoo.comFresh Tracks Therapeutics Announces Hearing Date and Notice of Proposed Consent Judgement Regarding Dissolution of CompanyDecember 6, 2024 | prnewswire.comFresh Tracks Therapeutics (OTC:FRTX) Stock, Short Interest ReportOctober 18, 2024 | benzinga.comFresh Tracks Therapeutics (OTC:FRTX) Stock Quotes, Forecast and News SummaryOctober 18, 2024 | benzinga.comFresh Tracks Therapeutics Inc (FRTX)August 31, 2024 | uk.investing.comAjofé Drops “One Time,” a Timeless Track with a Fresh BeatAugust 30, 2024 | thisdaylive.comFresh Tracks Therapeutics Announces Delaware Petition Filed Seeking Appointment of Custodian for Eventual Dissolution of CompanyJune 17, 2024 | globenewswire.comFresh Tracks Therapeutics Inc. (FRTX) Institutional HoldingsMay 25, 2024 | nasdaq.comExploration capital buys fresh tracks therapeutics shares worth over $19kApril 25, 2024 | investing.comExploration capital purchases Fresh Tracks Therapeutics stock worth $2,805April 13, 2024 | investing.comFresh Tracks Therapeutics, Inc.: Fresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15thFebruary 16, 2024 | finanznachrichten.deFresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15thFebruary 14, 2024 | finance.yahoo.comFresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15thFebruary 14, 2024 | globenewswire.comFresh Tracks Therapeutics IncJanuary 3, 2024 | morningstar.comFresh Tracks leaders doubt they have support for liquidationDecember 28, 2023 | bizwest.comFresh Tracks Therapeutics Announces Plan to Hold New Special Meeting of Stockholders on February 15thDecember 27, 2023 | finance.yahoo.comFresh Tracks Therapeutics, Inc.: Fresh Tracks Therapeutics Announces Listing on OTC Pink MarketDecember 20, 2023 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Companies to Buy on This Early Cycle RecoveryBy Gabriel Osorio-Mazilli | June 3, 2025View 3 Companies to Buy on This Early Cycle RecoveryThese Are the Only 6 Stock Stocks in NVIDIA's 13F PortfolioBy Leo Miller | May 22, 2025View These Are the Only 6 Stock Stocks in NVIDIA's 13F Portfolio3 Mid-Cap Stocks Turning Heads in AI, Automation, & CybersecurityBy Nathan Reiff | May 16, 2025View 3 Mid-Cap Stocks Turning Heads in AI, Automation, & CybersecurityIn a Historic Shift, 2 Cybersecurity Stocks Plan to Buyback StockBy Leo Miller | June 9, 2025View In a Historic Shift, 2 Cybersecurity Stocks Plan to Buyback StockBuy The Dip in Okta, There’s Nothing Wrong With the OutlookBy Thomas Hughes | June 2, 2025View Buy The Dip in Okta, There’s Nothing Wrong With the OutlookCUR, ALBT, FRTX, and EVAX Company DescriptionsAvalon GloboCare NASDAQ:ALBT$3.15 +0.13 (+4.30%) Closing price 06/13/2025 03:59 PM EasternExtended Trading$3.13 -0.02 (-0.60%) As of 06/13/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.Neuralstem NASDAQ:CURNeuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the treatment-refractory depression, Angelman Syndrome, Alzheimer's disease, ischemic stroke, diabetic neuropathy, irradiation-induced cognitive deficit, and long-term potentiation enhancement. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease; Phase II clinical trial for the treatment of chronic ischemic stroke; and Phase I clinical trials for the treatment of chronic spinal cord injury, as well as is in preclinical study for the traumatic brain injury. In addition, it develops NSI-532, which is in preclinical study for treatment of Alzheimer's disease; and NSI-777 that is in preclinical study for treatment of human demyelinating diseases. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.Evaxion Biotech A/S NASDAQ:EVAX$2.77 -0.20 (-6.73%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$2.80 +0.03 (+0.94%) As of 06/13/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.Fresh Tracks Therapeutics NASDAQ:FRTX$0.94 -0.01 (-0.53%) As of 02/28/2025Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
